PRME
Prime Medicine, Inc.
There isn't enough reported data to score PRME yet.
PRME Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PRME's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
PRME PE Valuation
PRME has no meaningful PE right now: it lost money over the past year.
PRME Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Moderate | |
| Low |
Analysts expect PRME's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
PRME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.96 | +$0.48 |
| Q2 2026 | -$1.06 | +$0.50 |
| Q1 2026 | -$1.23 | +$0.38 |
| Q4 2025 | -$1.35 | +$0.30 |
| Q3 2025 | -$1.44 | +$0.62 |
| Q2 2025 | -$1.56 | +$0.61 |
| Q1 2025 | -$1.61 | +$0.57 |
| Q4 2024 | -$1.65 | +$0.53 |
PRME is still losing money, but far less than before: $0.96 per share over the past year, against $3.02 at its worst in late 2022.
PRME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2M | +244% |
| Q4 2025 | $838K | -62% |
| Q3 2025 | $1.2M | +486% |
| Q1 2025 | $1.5M | +146% |
PRME's revenue is growing: $4M last quarter, up 190% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -948% | +3458 points |
| Q4 2025 | -5800% | -3775 points |
| Q3 2025 | -4406% | +21542 points |
| Q2 2025 | -4787% | N/A |
| Q1 2025 | -3603% | +4576 points |
| Q4 2024 | -2026% | N/A |
| Q3 2024 | -25948% | N/A |
| Q1 2024 | -8180% | N/A |
PRME's operating margin was −948% last quarter, up 2656 points from the same quarter a year ago.
PRME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37M | -$1.7M |
| Q2 2026 | -$41.1M | +$1.9M |
| Q1 2026 | -$42.9M | +$8.4M |
| Q4 2025 | -$37.5M | -360% |
| Q3 2025 | -$35.3M | -$8.1M |
| Q2 2025 | -$43M | +$4.4M |
| Q1 2025 | -$51.3M | +$18.8M |
| Q4 2024 | $14.5M | +$60.2M |
PRME has burned cash in almost every quarter: −$159M over the past year, against −$115M the year before.
PRME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +632K shares |
| 1 year | +11% | +17.4M shares |
| 3 years | +97% | +87.4M shares |
| 5 years | +86% | +82.1M shares |
PRME has 178M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q4 2019 | — |
PRME Net Leverage
PRME's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PRME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.1 | Neutral |
| Stochastic | 53.0 | Neutral |
PRME's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
PRME PE vs Healthcare Sector
PRME has no meaningful PE right now: it lost money over the past year.
PRME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 2.9% above |
| 20 week MA | $3.50 | 11% above |
| 50 week MA | $3.54 | 9.9% above |
| 100 week MA | $3.31 | 18% above |
| 200 week MA | $6.15 | 37% below |
PRME has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 37% below its 200-week average.
PRME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $15.8 | $17.8 | +13% |
| 2023 | $17.8 | $8.86 | -50% |
| 2024 | $8.86 | $2.90 | -67% |
| 2025 | $2.90 | $3.50 | +21% |
| 2026 YTD | $3.50 | $3.89 | +11% |
PRME has finished lower in two of the last four years. It's up 11% so far in 2026.